← 產業報告目錄
Botulinum Toxins Market by Product (Botox, Dysport, Jeuveau, Myobloc), Application (Cosmetic (Wrinkle Removal, Contouring, Skin rejuvenation), Therapeutic (OAB, Migraine, Spasm, Pain)), Volume, End User (Clinics, Center), Region - Global Forecast to 2030
授權報價
| Single User Licence | $4,950 USD |
| Multi User Licence | $6,650 USD |
| Corporate User Licence | $8,150 USD |
| Global User Licence | $10,000 USD |
報告摘要
The global botulinum toxins market is projected to reach USD 15.7 billion by 2030 from USD 8.9 billion in 2025, at a CAGR of 11.7% during the forecast period.
The growth of the market can be attributed to the increasing societal and occupational emphasis on looking youthful, especially in urban and professional environments. This trend encourages more individuals to seek cosmetic procedures, including the use of botulinum toxins. In developing countries, rising disposable incomes and exposure to urban lifestyles are creating new patient demographics, which significantly increases the demand for botulinum toxins. These factors are expected to drive the market for botulinum toxins during the forecast period.
“Based on product, Botox held the largest share of the botulinum toxins market in 2024.”
The botulinum toxins market is divided by product into major brands, including Botox, Dysport, Jeuveau, Myobloc, Xeomin, and other products. In 2024, Botox held the largest share of the market. The brand has established a strong reputation for clinical reliability, which instills confidence among cosmetologists, dermatologists, and aestheticians, as well as trust from end users such as clinics, spas, and hospitals. Botox offers a wide range of applications and demonstrates a safe and effective profile compared to its competitors.
Botox is utilized in various medical fields, including neurology, dermatology, urology, ophthalmology, and rehabilitation medicine, contributing to its increasing demand. Additionally, Botox provides extensive training modules and patient support programs. These factors have enabled Botox to surpass its competitors and secure a leading position in the botulinum toxins market.
“Based on type, the type A botulinum toxins segment held the largest share of the market in 2024.”
The botulinum toxins market is divided into two main categories based on type: type A and type B botulinum toxins. Type A botulinum toxins occupy a significant share of the global market, primarily due to their proven clinical effectiveness and long history of regulatory approvals. Being the first serotype in this category, type A is supported by substantial evidence demonstrating its safety and efficacy in both therapeutic and aesthetic applications.
Type A is authorized for a wide range of uses around the world, including treatments for chronic migraines, spasticity, and reducing facial wrinkles, which contributes to its widespread adoption. Additionally, type A offers a longer-lasting effect, typically lasting between three and six months, resulting in fewer treatment sessions and greater patient convenience.
These factors reinforce type A’s dominant position in manufacturing, sales, and demand within the botulinum toxins industry. In comparison, type A is preferred over type B because it provides effects lasting longer (up to six months) and has more extensive regulatory approvals for aesthetic and therapeutic purposes. It is also more potent at smaller doses and less likely to develop antibody resistance. Furthermore, type A is widely recognized among physicians, supported by extensive clinical experience and research, which cements its leading market position globally.
"Based on applications, the aesthetics segment commanded the largest market share in 2024.”
The aesthetics segment, particularly wrinkle removal, is expected to dominate the botulinum toxins market. In 2024, wrinkle removal continues to be a popular and well-recognized application of botulinum toxins, especially among adults seeking non-surgical anti-aging solutions. Clinics report high patient volumes, primarily for the treatment of forehead lines, crow’s feet, and glabellar (frown) lines. This popularity is attributed to the visible and relatively quick results, along with fewer treatment cycles needed, making it widely accepted across diverse demographics. The procedure duration is short, and the results are noticeable quickly, leading to its prominence among non-surgical options.
“Based on end users, the dermatology clinics & hospitals segment accounted for the largest share in 2024.”
The global botulinum toxins market is segmented by end user into dermatology clinics & hospitals, beauty centers, medical spas, and other end users. In 2024, dermatology clinics & hospitals witnessed a significant demand for botulinum toxin products, as they serve as primary providers for both aesthetic and medical procedures.
Dermatology clinics primarily focus on cosmetic treatments, such as wrinkle reduction and facial contouring, which are among the most common applications of botulinum toxins. In contrast, hospitals use these toxins to treat various medical conditions, including muscle spasticity, chronic migraines, and dystonia. With their well-equipped facilities, access to trained professionals, and capacity to manage both routine and complex cases, hospitals and clinics are key players that drive consistent usage of botulinum toxin products.
“The market in North America is expected to hold a significant market share for botulinum toxins throughout the forecast period.”
The botulinum toxins market comprises five key regions: North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2024, the North America region held a significant market share for botulinum toxins. This growth is primarily attributed to a strong healthcare infrastructure and the considerable disposable income of the population. North America is also home to several major manufacturers of botulinum toxins, fostering a sustainable ecosystem of buyers, distributors, and suppliers. These factors are anticipated to contribute to the growth of the botulinum toxins market in North America.
A breakdown of the primary participants referred to for this report is provided below:
• By Company Type: Tier 1 (35%), Tier 2 (45%), and Tier 3 (20%)
• By Designation: C-level Executives (35%), Directors (25%), and Others (40%)
• By Region: North America (40%), Europe (30%), Asia Pacific (20%), Latin America (5%), and the Middle East & Africa (5%)
The key players profiled in the botulinum toxins market are by AbbVie Inc. (US), Ipsen Biopharmaceuticals Inc. (France), Galderma (Switzerland), Hugel, Inc. (South Korea), Revance Therapeutics, Inc. (US), Evolus, Inc. (US), Medytox, Inc. (South Korea), Merz Pharmaceuticals GmbH (Germany), Supernus Pharmaceuticals, Inc. (US), Daewoong Pharmaceutical Co., Ltd. (South Korea), Huons Co., Ltd. (South Korea), Eisai Co., Ltd. (Japan) and Hugh Source (International) Ltd. (Hong Kong).
Research Coverage
The research report examines the botulinum toxins market by product, type, application, end user, and region. This research examines the factors contributing to market expansion, analyzes the challenges and opportunities currently faced by various industries, and provides details on the competitive landscape, including both market leaders and small to medium-sized enterprises. Additionally, it estimates the revenue generated by different market segments across five regions and includes a micromarket analysis.
Reasons to Buy the Report
The report will assist market leaders and new entrants by providing accurate revenue estimates for the overall botulinum toxins market and its subsegments. It will help stakeholders understand the competitive landscape, allowing them to position their businesses more effectively and develop appropriate go-to-market strategies. Additionally, the report offers insights into the market dynamics, including key drivers, restraints, challenges, and opportunities.
This report provides insightful data on the following points:
• Market Penetration: In-depth coverage of product portfolios offered by the top players in the botulinum toxins market.
• Product Development/Innovation: In-depth coverage of product portfolios offered by the top players in the botulinum toxins market.
• Market Development: Insightful data on profitable developing areas.
• Market Diversification: Details about recent developments and advancements in the botulinum toxins market.
• Competitive Assessment: Extensive assessment of the products, growth tactics, revenue projections, and market categories of the top competitors.
目錄 Table of Contents
1 INTRODUCTION 24
1.1 STUDY OBJECTIVES 24
1.2 MARKET DEFINITION 24
1.3 STUDY SCOPE 25
1.3.1 MARKET SEGMENTATION & REGIONAL SCOPE 25
1.3.2 INCLUSIONS & EXCLUSIONS 26
1.3.3 YEARS CONSIDERED 27
1.3.4 CURRENCY CONSIDERED 27
1.4 STAKEHOLDERS 27
2 RESEARCH METHODOLOGY 28
2.1 RESEARCH DATA 28
2.1.1 SECONDARY RESEARCH 29
2.1.1.1 Key secondary sources 30
2.1.1.2 Key data from secondary sources 31
2.1.1.3 Objectives of secondary research 31
2.1.2 PRIMARY RESEARCH 32
2.1.2.1 Key primary sources 32
2.2 MARKET SIZE ESTIMATION 34
2.2.1 BOTTOM-UP APPROACH 35
2.2.1.1 Company revenue estimation 36
2.2.1.2 Customer-based market estimation 36
2.2.1.3 Primary interviews 37
2.2.2 TOP-DOWN APPROACH 37
2.3 GROWTH RATE ASSUMPTIONS 39
2.4 DATA TRIANGULATION 41
2.5 STUDY ASSUMPTIONS 42
2.6 RESEARCH LIMITATIONS 42
2.7 RISK ANALYSIS 43
3 EXECUTIVE SUMMARY 44
4 PREMIUM INSIGHTS 47
4.1 BOTULINUM TOXINS MARKET OVERVIEW 47
4.2 ASIA PACIFIC: BOTULINUM TOXINS MARKET, BY APPLICATION
AND COUNTRY, 2024 (USD MILLION) 48
4.3 BOTULINUM TOXINS MARKET: EMERGING VS. DEVELOPED MARKETS,
2025 VS. 2030 (USD MILLION) 49
4.4 BOTULINUM TOXINS MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES 50
5 MARKET OVERVIEW 51
5.1 INTRODUCTION 51
5.2 MARKET DYNAMICS 51
5.2.1 DRIVERS 52
5.2.1.1 Increased adoption in therapeutic indications 52
5.2.1.2 Reduced out-of-pocket expenditure due to sufficient reimbursement schemes 53
5.2.1.3 Aesthetic consciousness among adults 53
5.2.1.4 Greater acceptance and normalization of botulinum toxins among millennials and Gen Z 53
5.2.2 RESTRAINTS 54
5.2.2.1 Risk of infection and safety concerns 54
5.2.2.2 Complex regulatory framework and compliance standards 54
5.2.3 OPPORTUNITIES 54
5.2.3.1 High growth opportunities in emerging economies 54
5.2.3.2 Formulation advancements and innovations for improved safety 55
5.2.4 CHALLENGES 55
5.2.4.1 High treatment costs 55
5.2.4.2 Social and cultural barriers 56
5.3 TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 56
5.4 PRICING ANALYSIS 57
5.4.1 AVERAGE SELLING PRICE TREND OF BOTULINUM TOXINS, BY KEY PLAYER, 2022–2024 57
5.4.2 AVERAGE SELLING PRICE TREND OF BOTULINUM TOXINS, BY REGION,
2022–2024 58
5.5 VALUE CHAIN ANALYSIS 59
5.5.1 RESEARCH & DEVELOPMENT 60
5.5.2 RAW MATERIAL PROCUREMENT AND MANUFACTURING 61
5.5.3 DISTRIBUTION AND MARKETING & SALES 61
5.5.4 AFTER-SALES SERVICES 61
5.6 SUPPLY CHAIN ANALYSIS 61
5.6.1 PROMINENT COMPANIES 62
5.6.2 SMALL & MEDIUM-SIZED ENTERPRISES 62
5.6.3 END USERS 62
5.7 ECOSYSTEM ANALYSIS 63
5.7.1 ROLE IN ECOSYSTEM 63
5.8 INVESTMENT & FUNDING SCENARIO 64
5.9 TECHNOLOGY ANALYSIS 65
5.9.1 KEY TECHNOLOGIES 65
5.9.1.1 Jet-based delivery systems 65
5.9.1.2 Facial imaging and mapping systems 66
5.9.2 COMPLEMENTARY TECHNOLOGIES 66
5.9.2.1 Laser, RF, & ultrasound-based devices 66
5.9.3 ADJACENT TECHNOLOGIES 66
5.9.3.1 3D imaging and AI-based facial mapping 66
5.10 PATENT ANALYSIS 66
5.10.1 INNOVATIONS AND PATENT REGISTRATIONS 68
5.11 TRADE ANALYSIS 68
5.11.1 IMPORT DATA FOR HS CODE 300290, 2020–2024 69
5.11.2 EXPORT DATA FOR HS CODE 300290, 2020–2024 70
5.12 KEY CONFERENCES & EVENTS, 2025–2026 71
5.13 CASE STUDY ANALYSIS 71
5.13.1 COMMERCIAL PARTNERSHIPS BY ANIKA THERAPEUTICS TO INCREASE MEDICAL AESTHETIC PRODUCT SALES 71
5.13.2 DIVISION OF BUSINESS BY MERZ BIOPHARMA TO HELP
EFFECIENTLY MEET CUSTOMER DEMANDS 72
5.13.3 COLLABORATIONS BETWEEN CANDELA CORPORATION AND SMES TO STREAMLINE LASER-BASED DEVICES 72
5.14 REGULATORY ANANLYSIS 73
5.14.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS 73
5.14.2 KEY REGULATORY GUIDELINES 75
5.14.2.1 North America 75
5.14.2.1.1 US 75
5.14.2.1.2 Canada 76
5.14.2.2 Europe 77
5.14.2.2.1 UK 77
5.14.2.2.2 France 78
5.14.2.2.3 Germany 78
5.14.2.3 Asia Pacific 79
5.14.2.3.1 China 79
5.14.2.3.2 Japan 79
5.14.2.3.3 India 80
5.14.2.4 Latin America 80
5.14.2.4.1 Brazil 80
5.14.2.5 Middle East & Africa 81
5.14.2.5.1 UAE 81
5.14.3 REGULATORY STANDARDS/APPROVALS 81
5.15 REIMBURSEMENT SCENARIO ANALYSIS 82
5.15.1 NORTH AMERICA 82
5.15.1.1 US 82
5.15.1.2 Canada 82
5.15.2 EUROPE 82
5.15.2.1 UK 82
5.15.2.2 Germany 82
5.15.2.3 France 82
5.15.2.4 Italy 82
5.15.2.5 Spain 83
5.15.3 ASIA PACIFIC 83
5.15.3.1 China 83
5.15.3.2 Japan 83
5.15.3.3 India 83
5.15.3.4 Australia 83
5.15.4 LATIN AMERICA 83
5.15.4.1 Brazil 83
5.15.4.2 Mexico 83
5.15.5 MIDDLE EAST & AFRICA 84
5.15.5.1 GCC Countries 84
5.15.5.2 Africa (Major Economies) 84
5.16 PORTER’S FIVE FORCE ANALYSIS 84
5.16.1 THREAT OF NEW ENTRANTS 85
5.16.2 THREAT OF SUBSTITUTES 85
5.16.3 BARGAINING POWER OF SUPPLIERS 86
5.16.4 BARGAINING POWER OF BUYERS 86
5.16.5 INTENSITY OF COMPETITIVE RIVALRY 86
5.17 KEY STAKEHOLDERS & BUYING CRITERIA 86
5.17.1 KEY STAKEHOLDERS IN BUYING PROCESS 86
5.17.2 BUYING CRITERIA 87
5.18 UNMET NEEDS 88
5.19 IMPACT OF 2025 US TARIFF ON BOTULINUM TOXINS MARKET 88
5.19.1 INTRODUCTION 88
5.19.2 KEY TARIFF RATES 89
5.19.3 PRICE IMPACT ANALYSIS 89
5.19.4 IMPACT ON COUNTRY/REGION 90
5.19.4.1 North America 90
5.19.4.1.1 US 90
5.19.4.2 Europe 90
5.19.4.3 Asia Pacific 90
5.19.5 IMPACT ON END-USE INDUSTRIES 90
5.20 IMPACT OF AI/GEN AI ON BOTULINUM TOXINS MARKET 90
5.20.1 MARKET POTENTIAL OF AI/GEN AI 90
5.20.2 AI USE CASES 91
5.20.3 KEY COMPANIES IMPLEMENTING AI/GEN AI 92
5.20.4 FUTURE OF AI/GEN AI 92
6 BOTULINUM TOXINS MARKET, BY PRODUCT 93
6.1 INTRODUCTION 94
6.2 BOTOX 94
6.2.1 USE IN THERAPEUTIC AND COSMETIC PROCEDURES TO
AUGMENT MARKET GROWTH 94
6.3 DYSPORT 95
6.3.1 FASTER ONSET DURATION AND LONG-LASTING EFFECT
TO BOOST MARKET ADOPTION 95
6.4 JEUVEAU 95
6.4.1 INTRODUCTION OF TECH-ENABLED PLATFORMS FOR
CONSUMER SUPPORT TO FUEL MARKET GROWTH 95
6.5 MYOBLOC 95
6.5.1 WIDE THERAPEUTIC PROFILE TO DRIVE MARKET 95
6.6 XEOMIN 96
6.6.1 STABLE THERAPEUTIC PERFORMANCE AND EFFECTIVE
FORMULATION TO FAVOR MARKET GROWTH 96
6.7 OTHER PRODUCTS 96
7 BOTULINUM TOXINS MARKET, BY TYPE 97
7.1 INTRODUCTION 98
7.2 TYPE A BOTULINUM TOXINS 98
7.2.1 GLOBAL CLINICAL ACCEPTANCE AND PROVEN EFFICACY
TO SUPPORT MARKET GROWTH 98
7.3 TYPE B BOTULINUM TOXINS 102
7.3.1 WIDE THERAPEUTIC UTILITY AND DISTINCT CLINICAL PROFILE
TO PROPEL MARKET GROWTH 102
8 BOTULINUM TOXINS MARKET, BY AGE GROUP 105
8.1 INTRODUCTION 106
8.2 17 YEARS OR YOUNGER 106
8.2.1 INCREASING THERAPEUTIC USE OF BOTOX TO PROPEL MARKET GROWTH AMONG YOUNGER PEOPLE 106
8.3 18–34 YEARS 107
8.3.1 GOOD TOLERABILITY AND IMPROVED PATIENT-REPORTED OUTCOMES TO DRIVE ADOPTION OF BOTOX TREATMENT 107
8.4 35–50 YEARS 108
8.4.1 NEED FOR APPEARANCE MAINTENANCE AND BETTER SOCIAL ENGAGEMENT TO FUEL MARKET GROWTH 108
8.5 51–64 YEARS OLD 109
8.5.1 SUSTAINED DEMAND FOR COSMETIC AND THERAPEUTIC INDICATIONS TO AUGMENT MARKET GROWTH 109
8.6 65 YEARS OR OLDER 109
8.6.1 HIGH DEMAND FOR FUNCTIONAL IMPROVEMENTS AND CONSERVATIVE AESTHETIC ENHANCEMENTS TO DRIVE MARKET 109
9 BOTULINUM TOXINS MARKET, BY APPLICATION 111
9.1 INTRODUCTION 112
9.2 COSMETIC APPLICATIONS 112
9.2.1 WRINKLE REMOVAL 113
9.2.1.1 Surge in beauty clinics and medical spas to support segment growth 113
9.2.2 FACIAL CONTOURING 115
9.2.2.1 Rising desire for natural results and growing appeal of minimally invasive procedures to propel segment growth 115
9.2.3 SKIN REJUVENATION 115
9.2.3.1 Increased adoption of minimally invasive facial enhancement procedures to boost market growth 115
9.3 THERAPEUTIC APPLICATIONS 116
9.3.1 PAIN MANAGEMENT 117
9.3.1.1 Rising need for pain management techniques to drive segment 117
9.3.2 OVERACTIVE BLADDER 118
9.3.2.1 Localized mechanism, strong efficacy, and long-lasting relief to spur demand for botulinum toxins among neurogenic patients 118
9.4 OTHER APPLICATIONS 119
10 BOTULINUM TOXINS MARKET, BY END USER 121
10.1 INTRODUCTION 122
10.2 DERMATOLOGY CLINICS & HOSPITALS 122
10.2.1 RISING TREND OF MEDICAL TOURISM AND INCREASING POPULARITY OF PLASTIC SURGERY TO SUPPORT MARKET GROWTH 122
10.3 BEAUTY CENTERS 123
10.3.1 GROWING INCLINATION TOWARD CUSTOMIZED TREATMENTS TO BOOST MARKET GROWTH 123
10.4 MEDICAL SPAS 124
10.4.1 INCREASING FOCUS ON CONVENIENCE, TREATMENT FLEXIBILITY, AND COST EFFECTIVENESS TO SPUR MARKET GROWTH 124
10.5 OTHER END USERS 125
11 BOTULINUM TOXINS MARKET, BY REGION 127
11.1 INTRODUCTION 128
11.2 NORTH AMERICA 129
11.2.1 MACROECONOMIC OUTLOOK FOR NORTH AMERICA 130
11.2.2 US 134
11.2.2.1 US to dominate North American botulinum toxins market during study period 134
11.2.3 CANADA 135
11.2.3.1 Preference for minimally invasive cosmetic procedures among aging individuals to drive market growth 135
11.3 EUROPE 135
11.3.1 MACROECONOMIC OUTLOOK FOR EUROPE 138
11.3.2 GERMANY 139
11.3.2.1 Selective reimbursement regimes and large number of cosmetic procedures to spur market demand 139
11.3.3 UK 140
11.3.3.1 Increased demand for Botox for cosmetic enhancements to propel market growth 140
11.3.4 FRANCE 141
11.3.4.1 Increased awareness and broader societal acceptance of cosmetic treatments to augment market growth 141
11.3.5 ITALY 142
11.3.5.1 Rising number of medical aesthetic procedures to aid market growth 142
11.3.6 SPAIN 143
11.3.6.1 Growing availability of safe and effective minimally invasive or non-invasive aesthetic treatments to aid market growth 143
11.3.7 REST OF EUROPE 144
11.4 ASIA PACIFIC 144
11.4.1 MACROECONOMIC OUTLOOK FOR ASIA PACIFIC 146
11.4.2 JAPAN 149
11.4.2.1 Popularity of medical tourism to increase demand for cosmetic treatments 149
11.4.3 CHINA 150
11.4.3.1 Surging demand for non-surgical aesthetic procedures to support market growth 150
11.4.4 INDIA 150
11.4.4.1 Lack of reimbursements for aesthetic treatments alongside social and ethical concerns to limit market growth 150
11.4.5 AUSTRALIA 151
11.4.5.1 Increased number of aesthetic procedures to grow market for botulinum toxins 151
11.4.6 SOUTH KOREA 152
11.4.6.1 Rising availability of safe and effective minimally invasive and non-invasive aesthetic procedures and products to drive market 152
11.4.7 REST OF ASIA PACIFIC 152
11.5 LATIN AMERICA 153
11.5.1 MACROECONOMIC OUTLOOK FOR LATIN AMERICA 155
11.5.2 BRAZIL 156
11.5.2.1 Rapid growth in medical tourism and high disposable incomes to expedite market growth 156
11.5.3 MEXICO 156
11.5.3.1 Rising influx of medical tourists from US to drive adoption of cost-effective cosmetic procedures 156
11.5.4 REST OF LATIN AMERICA 157
11.6 MIDDLE EAST & AFRICA 158
11.6.1 MACROECONOMIC OUTLOOK FOR MIDDLE EAST & AFRICA 158
11.6.2 GCC COUNTRIES 161
11.6.2.1 Favorable government policies to propel market growth 161
11.6.3 REST OF MIDDLE EAST & AFRICA 162
12 COMPETITIVE LANDSCAPE 163
12.1 INTRODUCTION 163
12.2 KEY PLAYERS’ STRATEGIES/RIGHT TO WIN 163
12.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN BOTULINUM TOXINS MARKET 163
12.3 REVENUE ANALYSIS, 2020–2024 165
12.4 MARKET SHARE ANALYSIS, 2024 166
12.4.1 MARKET RANKING OF KEY PLAYERS, 2024 168
12.5 COMPANY VALUATION & FINANCIAL METRICS 168
12.5.1 FINANCIAL METRICS 168
12.5.2 COMPANY VALUATION 169
12.6 BRAND/PRODUCT COMPARISON 170
12.7 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2024 171
12.7.1 STARS 171
12.7.2 PERVASIVE PLAYERS 171
12.7.3 EMERGING LEADERS 171
12.7.4 PARTICIPANTS 171
12.7.5 COMPANY FOOTPRINT: KEY PLAYERS, 2024 173
12.7.5.1 Company footprint 173
12.7.5.2 Region footprint 174
12.7.5.3 Type footprint 175
12.7.5.4 Application footprint 176
12.7.5.5 End-user footprint 177
12.8 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2024 178
12.8.1 PROGRESSIVE COMPANIES 178
12.8.2 RESPONSIVE COMPANIES 178
12.8.3 DYNAMIC COMPANIES 178
12.8.4 STARTING BLOCKS 178
12.8.5 COMPETITIVE BENCHMARKING OF STARTUPS/SMES, 2024 180
12.8.5.1 Detailed list of key startups/SMEs 180
12.8.5.2 Competitive benchmarking of key startups/SMEs 181
12.9 COMPETITIVE SCENARIO 182
12.9.1 PRODUCT LAUNCHES & APPROVALS 182
12.9.2 DEALS 183
12.9.3 EXPANSIONS 184
13 COMPANY PROFILES 185
13.1 KEY PLAYERS 185
13.1.1 ABBVIE INC. 185
13.1.1.1 Business overview 185
13.1.1.2 Products offered 186
13.1.1.3 Recent developments 187
13.1.1.3.1 Deals 187
13.1.1.3.2 Expansions 188
13.1.1.3.3 Other developments 188
13.1.1.4 MnM view 188
13.1.1.4.1 Key strengths 188
13.1.1.4.2 Strategic choices 189
13.1.1.4.3 Weaknesses & competitive threats 189
13.1.2 IPSEN BIOPHARMACEUTICALS, INC. 190
13.1.2.1 Business overview 190
13.1.2.2 Products offered 191
13.1.2.3 Recent developments 192
13.1.2.3.1 Product approvals 192
13.1.2.3.2 Expansions 192
13.1.2.3.3 Other developments 192
13.1.2.4 MnM view 193
13.1.2.4.1 Key strengths 193
13.1.2.4.2 Strategic choices 193
13.1.2.4.3 Weaknesses & competitive threats 193
13.1.3 GALDERMA 194
13.1.3.1 Business overview 194
13.1.3.2 Products offered 195
13.1.3.3 Recent developments 196
13.1.3.3.1 Product launches 196
13.1.3.3.2 Deals 196
13.1.3.3.3 Expansions 196
13.1.3.4 MnM view 197
13.1.3.4.1 Key strengths 197
13.1.3.4.2 Strategic choices 197
13.1.3.4.3 Weaknesses & competitive threats 197
13.1.4 HUGEL, INC. 198
13.1.4.1 Business overview 198
13.1.4.2 Products offered 199
13.1.4.3 Recent developments 200
13.1.4.3.1 Product approvals 200
13.1.4.3.2 Deals 200
13.1.4.3.3 Expansions 201
13.1.4.4 MnM view 201
13.1.4.4.1 Key strengths 201
13.1.4.4.2 Strategic choices 201
13.1.4.4.3 Weaknesses & competitive threats 201
13.1.5 REVANCE 202
13.1.5.1 Business overview 202
13.1.5.2 Products offered 202
13.1.5.3 Recent developments 203
13.1.5.3.1 Product launches & approvals 203
13.1.5.3.2 Deals 203
13.1.5.4 MnM view 203
13.1.5.4.1 Key strengths 203
13.1.5.4.2 Strategic choices 204
13.1.5.4.3 Weaknesses & competitive threats 204
13.1.6 EVOLUS, INC. 205
13.1.6.1 Business overview 205
13.1.6.2 Products offered 206
13.1.6.3 Recent developments 207
13.1.6.3.1 Product launches & approvals 207
13.1.6.3.2 Deals 207
13.1.7 MEDYTOX 208
13.1.7.1 Business overview 208
13.1.7.2 Products offered 209
13.1.7.3 Recent developments 210
13.1.7.3.1 Product approvals 210
13.1.7.3.2 Deals 210
13.1.8 MERZ PHARMA 211
13.1.8.1 Business overview 211
13.1.8.2 Products offered 211
13.1.8.3 Recent developments 212
13.1.8.3.1 Product approvals 212
13.1.9 SUPERNUS PHARMACEUTICALS, INC. 213
13.1.9.1 Business overview 213
13.1.9.2 Products offered 214
13.1.10 DAEWOONG PHARMACEUTICAL CO., LTD. 215
13.1.10.1 Business overview 215
13.1.10.2 Products offered 215
13.1.10.3 Recent developments 216
13.1.10.3.1 Product launches & approvals 216
13.1.11 HUONS 217
13.1.11.1 Business overview 217
13.1.11.2 Products offered 218
13.1.11.3 Recent developments 218
13.1.11.3.1 Product launches & approvals 218
13.1.12 EISAI CO., LTD. 219
13.1.12.1 Business overview 219
13.1.12.2 Products offered 220
13.1.13 HUGH SOURCE (INTERNATIONAL) LTD. 221
13.1.13.1 Business overview 221
13.1.13.2 Products offered 221
13.2 OTHER PLAYERS 222
13.2.1 DERMAX CO., LTD. 222
13.2.2 GUFIC BIOSCIENCES 222
13.2.3 OCEAN PHARMACEUTICAL 223
13.2.4 CROMA-PHARMA GMBH 223
13.2.5 MICROGEN 224
13.2.6 JDBIO CO., LTD. 224
13.2.7 CKD BIO 225
13.2.8 ATRAZIST ARAY CO. 225
13.2.9 GUANGZHOU AOMA BUSINESS CO., LTD. 226
13.2.10 JETEMA CO., LTD. 226
13.2.11 SINOPHARM GROUP CO., LTD. 227
13.2.12 QUFU HANTANG BIOTECHNOLOGY CO., LTD. 227
14 APPENDIX 228
14.1 DISCUSSION GUIDE 228
14.2 KNOWLEDGESTORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 232
14.3 CUSTOMIZATION OPTIONS 234
14.4 RELATED REPORTS 234
14.5 AUTHOR DETAILS 235
圖表清單 List of Tables & Figures
TABLE 1 BOTULINUM TOXINS MARKET: INCLUSIONS & EXCLUSIONS 26
TABLE 2 BOTULINUM TOXINS MARKET: STUDY ASSUMPTIONS 42
TABLE 3 BOTULINUM TOXINS MARKET: RISK ANALYSIS 43
TABLE 4 BOTULINUM TOXINS MARKET: IMPACT ANALYSIS OF MARKET DYNAMICS 52
TABLE 5 AVERAGE SELLING PRICE TREND OF BOTULINUM TOXINS, BY KEY PLAYER,
2022–2024 (USD) 58
TABLE 6 AVERAGE SELLING PRICE TREND OF BOTULINUM TOXINS, BY REGION,
2022–2024 (USD THOUSAND) 59
TABLE 7 BOTULINUM TOXINS MARKET: ROLE IN ECOSYSTEM 63
TABLE 8 BOTULINUM TOXINS MARKET: INNOVATIONS AND PATENT REGISTRATIONS, 2024 68
TABLE 9 IMPORT SCENARIO FOR HS CODE 300290, BY COUNTRY, 2020–2024 (USD) 69
TABLE 10 EXPORT SCENARIO FOR HS CODE 300290, BY COUNTRY, 2020–2024 (USD) 70
TABLE 11 BOTULINUM TOXINS MARKET: LIST OF KEY CONFERENCES & EVENTS,
JANUARY 2025–DECEMBER 2026 71
TABLE 12 CASE STUDY 1: COMMERCIAL PARTNERSHIPS BY ANIKA THERAPEUTICS TO INCREASE MEDICAL AESTHETIC PRODUCT SALES 71
TABLE 13 CASE STUDY 2: DIVISION OF BUSINESS BY MERZ BIOPHARMA TO HELP EFFECIENTLY MEET CUSTOMER DEMANDS 72
TABLE 14 CASE STUDY 3: COLLABORATIONS BETWEEN CANDELA CORPORATION AND SMES TO STREAMLINE LASER-BASED DEVICES 72
TABLE 15 NORTH AMERICA: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 73
TABLE 16 EUROPE: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 73
TABLE 17 ASIA PACIFIC: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 74
TABLE 18 REST OF THE WORLD: REGULATORY BODIES, GOVERNMENT AGENCIES,
AND OTHER ORGANIZATIONS 74
TABLE 19 REGULATORY STANDARD/APPROVAL AUTHORIZATION AND CLASS OF APPROVAL FOR PRODUCTS USED IN AESTHETIC PROCEDURES, BY COUNTRY 81
TABLE 20 BOTULINUM TOXINS MARKET: PORTER’S FIVE FORCES 84
TABLE 21 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS OF BOTULINUM TOXINS, BY TYPE 87
TABLE 22 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS OF BOTULINUM TOXINS, BY END USER 88
TABLE 23 BOTULINUM TOXINS MARKET: UNMET NEEDS 88
TABLE 24 RECIPROCAL TARIFF RATES ADJUSTED BY US, 2024 89
TABLE 25 KEY COMPANIES IMPLEMENTING AI/GEN AI IN BOTULINUM TOXINS MARKET 92
TABLE 26 BOTULINUM TOXINS MARKET, BY PRODUCT, 2023–2030 (USD MILLION) 94
TABLE 27 BOTULINUM TOXINS MARKET, BY TYPE, 2023–2030 (USD MILLION) 98
TABLE 28 TYPE A BOTULINUM TOXINS MARKET, BY REGION, 2023–2030 (USD MILLION) 99
TABLE 29 NORTH AMERICA: TYPE A BOTULINUM TOXINS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 99
TABLE 30 EUROPE: TYPE A BOTULINUM TOXINS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 100
TABLE 31 ASIA PACIFIC: TYPE A BOTULINUM TOXINS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 100
TABLE 32 LATIN AMERICA: TYPE A BOTULINUM TOXINS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 101
TABLE 33 MIDDLE EAST & AFRICA: TYPE A BOTULINUM TOXINS MARKET,
2023–2030 (USD MILLION) 101
TABLE 34 TYPE A BOTULINUM TOXINS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 101
TABLE 35 TYPE A BOTULINUM TOXINS MARKET, BY END USER, 2023–2030 (USD MILLION) 102
TABLE 36 TYPE B BOTULINUM TOXINS MARKET, BY REGION, 2023–2030 (USD MILLION) 103
TABLE 37 NORTH AMERICA: TYPE B BOTULINUM TOXINS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 103
TABLE 38 TYPE B BOTULINUM TOXINS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 103
TABLE 39 TYPE B BOTULINUM TOXINS MARKET, BY END USER, 2023–2030 (USD MILLION) 104
TABLE 40 BOTULINUM TOXINS MARKET, BY AGE GROUP, 2023–2030 (USD MILLION) 106
TABLE 41 BOTULINUM TOXINS MARKET FOR 17 YEARS OR YOUNGER, BY REGION,
2023–2030 (USD MILLION) 107
TABLE 42 BOTULINUM TOXINS MARKET FOR 18–34 YEARS, BY REGION,
2023–2030 (USD MILLION) 108
TABLE 43 BOTULINUM TOXINS MARKET FOR 35–50 YEARS, BY REGION,
2023–2030 (USD MILLION) 108
TABLE 44 BOTULINUM TOXINS MARKET FOR 51–64 YEARS, BY REGION,
2023–2030 (USD MILLION) 109
TABLE 45 BOTULINUM TOXINS MARKET FOR 65 YEARS OR OLDER, BY REGION,
2023–2030 (USD MILLION) 110
TABLE 46 BOTULINUM TOXINS MARKET, BY APPLICATION, 2023–2030 (USD MILLION) 112
TABLE 47 BOTULINUM TOXINS MARKET FOR COSMETIC APPLICATIONS, BY TYPE,
2023–2030 (USD MILLION) 113
TABLE 48 BOTULINUM TOXINS MARKET FOR COSMETIC APPLICATIONS, BY REGION,
2023–2030 (USD MILLION) 113
TABLE 49 WRINKLE REMOVAL MARKET, BY REGION, 2023–2030 (USD MILLION) 114
TABLE 50 FACIAL CONTOURING MARKET, BY REGION, 2023–2030 (USD MILLION) 115
TABLE 51 SKIN REJUVENATION MARKET, BY REGION, 2023–2030 (USD MILLION) 116
TABLE 52 BOTULINUM TOXINS MARKET FOR THERAPEUTIC APPLICATIONS, BY TYPE,
2023–2030 (USD MILLION) 117
TABLE 53 BOTULINUM TOXINS MARKET FOR THERAPEUTIC APPLICATIONS, BY REGION, 2023–2030 (USD MILLION) 117
TABLE 54 PAIN MANAGEMENT MARKET, BY TYPE, 2023–2030 (USD MILLION) 118
TABLE 55 PAIN MANAGEMENT MARKET, BY REGION, 2023–2030 (USD MILLION) 118
TABLE 56 OVERACTIVE BLADDER MARKET, BY REGION, 2023–2030 (USD MILLION) 119
TABLE 57 BOTULINUM TOXINS MARKET FOR OTHER APPLICATIONS, BY REGION,
2023–2030 (USD MILLION) 120
TABLE 58 BOTULINUM TOXINS MARKET, BY END USER, 2023–2030 (USD MILLION) 122
TABLE 59 BOTULINUM TOXINS MARKET FOR DERMATOLOGY CLINICS & HOSPITALS,
BY REGION, 2023–2030 (USD MILLION) 123
TABLE 60 BOTULINUM TOXINS MARKET FOR BEAUTY CENTERS, BY REGION,
2023–2030 (USD MILLION) 124
TABLE 61 BOTULINUM TOXINS MARKET FOR MEDICAL SPAS, BY REGION,
2023–2030 (USD MILLION) 125
TABLE 62 BOTULINUM TOXINS MARKET FOR OTHER END USERS, BY REGION,
2023–2030 (USD MILLION) 126
TABLE 63 BOTULINUM TOXINS MARKET, BY REGION, 2023–2030 (USD MILLION) 128
TABLE 64 GLOBAL: NUMBER OF BOTULINUM TOXIN PROCEDURES, 2021–2023 (UNITS) 128
TABLE 65 NORTH AMERICA: KEY MACROINDICATORS 131
TABLE 66 NORTH AMERICA: BOTULINUM TOXINS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 131
TABLE 67 NORTH AMERICA: BOTULINUM TOXINS MARKET, BY TYPE,
2023–2030 (USD MILLION) 132
TABLE 68 NORTH AMERICA: BOTULINUM TOXINS MARKET, BY AGE GROUP,
2023–2030 (USD MILLION) 132
TABLE 69 NORTH AMERICA: BOTULINUM TOXINS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 133
TABLE 70 NORTH AMERICA: BOTULINUM TOXINS MARKET, BY END USER,
2023–2030 (USD MILLION) 133
TABLE 71 US: NUMBER OF BOTULINUM TOXIN PROCEDURES, 2021–2023 (UNITS) 134
TABLE 72 US: BOTULINUM TOXINS MARKET, BY TYPE, 2023–2030 (USD MILLION) 134
TABLE 73 CANADA: BOTULINUM TOXINS MARKET, BY TYPE, 2023–2030 (USD MILLION) 135
TABLE 74 EUROPE: BOTULINUM TOXINS MARKET, BY COUNTRY, 2023–2030 (USD MILLION) 136
TABLE 75 EUROPE: BOTULINUM TOXINS MARKET, BY TYPE, 2023–2030 (USD MILLION) 136
TABLE 76 EUROPE: BOTULINUM TOXINS MARKET, BY AGE GROUP,
2023–2030 (USD MILLION) 137
TABLE 77 EUROPE: BOTULINUM TOXINS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 137
TABLE 78 EUROPE: BOTULINUM TOXINS MARKET, BY END USER,
2023–2030 (USD MILLION) 138
TABLE 79 EUROPE: KEY MACROINDICATORS 139
TABLE 80 GERMANY: NUMBER OF BOTULINUM TOXIN PROCEDURES, 2021–2023 (UNITS) 139
TABLE 81 GERMANY: BOTULINUM TOXINS MARKET, BY TYPE, 2023–2030 (USD MILLION) 140
TABLE 82 UK: NUMBER OF BOTULINUM TOXIN PROCEDURES, 2021–2023 (UNITS) 140
TABLE 83 UK: BOTULINUM TOXINS MARKET, BY TYPE, 2023–2030 (USD MILLION) 140
TABLE 84 FRANCE: NUMBER OF BOTULINUM TOXIN PROCEDURES, 2021–2023 (UNITS) 141
TABLE 85 FRANCE: BOTULINUM TOXINS MARKET, BY TYPE, 2023–2030 (USD MILLION) 141
TABLE 86 ITALY: NUMBER OF BOTULINUM TOXIN PROCEDURES, 2021–2023 (UNITS) 142
TABLE 87 ITALY: BOTULINUM TOXINS MARKET, BY TYPE, 2023–2030 (USD MILLION) 142
TABLE 88 SPAIN: NUMBER OF BOTULINUM TOXIN PROCEDURES, 2021–2023 (UNITS) 143
TABLE 89 SPAIN: BOTULINUM TOXINS MARKET, BY TYPE, 2023–2030 (USD MILLION) 143
TABLE 90 REST OF EUROPE: BOTULINUM TOXINS MARKET, BY TYPE,
2023–2030 (USD MILLION) 144
TABLE 91 ASIA PACIFIC: KEY MACROINDICATORS 146
TABLE 92 ASIA PACIFIC: BOTULINUM TOXINS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 147
TABLE 93 ASIA PACIFIC: BOTULINUM TOXINS MARKET, BY TYPE, 2023–2030 (USD MILLION) 147
TABLE 94 ASIA PACIFIC: BOTULINUM TOXINS MARKET, BY AGE GROUP,
2023–2030 (USD MILLION) 148
TABLE 95 ASIA PACIFIC: BOTULINUM TOXINS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 148
TABLE 96 ASIA PACIFIC: BOTULINUM TOXINS MARKET, BY END USER,
2023–2030 (USD MILLION) 149
TABLE 97 JAPAN: BOTULINUM TOXINS MARKET, BY TYPE, 2023–2030 (USD MILLION) 149
TABLE 98 CHINA: BOTULINUM TOXINS MARKET, BY TYPE, 2023–2030 (USD MILLION) 150
TABLE 99 INDIA: NUMBER OF BOTULINUM TOXIN PROCEDURES, 2021–2023 (UNITS) 151
TABLE 100 INDIA: BOTULINUM TOXINS MARKET, BY TYPE, 2023–2030 (USD MILLION) 151
TABLE 101 AUSTRALIA: BOTULINUM TOXINS MARKET, BY TYPE, 2023–2030 (USD MILLION) 151
TABLE 102 SOUTH KOREA: BOTULINUM TOXINS MARKET, BY TYPE,
2023–2030 (USD MILLION) 152
TABLE 103 REST OF ASIA PACIFIC: BOTULINUM TOXINS MARKET, BY TYPE,
2023–2030 (USD MILLION) 153
TABLE 104 LATIN AMERICA: BOTULINUM TOXINS MARKET, BY COUNTRY,
2023–2030 (USD MILLION) 153
TABLE 105 LATIN AMERICA: BOTULINUM TOXINS MARKET, BY TYPE,
2023–2030 (USD MILLION) 154
TABLE 106 LATIN AMERICA: BOTULINUM TOXINS MARKET, BY AGE GROUP,
2023–2030 (USD MILLION) 154
TABLE 107 LATIN AMERICA: BOTULINUM TOXINS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 154
TABLE 108 LATIN AMERICA: BOTULINUM TOXINS MARKET, BY END USER,
2023–2030 (USD MILLION) 155
TABLE 109 LATIN AMERICA: KEY MACROINDICATORS 155
TABLE 110 BRAZIL: NUMBER OF BOTULINUM TOXIN PROCEDURES, 2021–2023 (UNITS) 156
TABLE 111 BRAZIL: BOTULINUM TOXINS MARKET, BY TYPE, 2023–2030 (USD MILLION) 156
TABLE 112 MEXICO: NUMBER OF BOTULINUM TOXIN PROCEDURES, 2021–2023 (UNITS) 157
TABLE 113 MEXICO: BOTULINUM TOXINS MARKET, BY TYPE, 2023–2030 (USD MILLION) 157
TABLE 114 REST OF LATIN AMERICA: BOTULINUM TOXINS MARKET, BY TYPE,
2023–2030 (USD MILLION) 158
TABLE 115 MIDDLE EAST & AFRICA: KEY MACROINDICATORS 159
TABLE 116 MIDDLE EAST & AFRICA: BOTULINUM TOXINS MARKET, BY REGION,
2023–2030 (USD MILLION) 159
TABLE 117 MIDDLE EAST & AFRICA: BOTULINUM TOXINS MARKET, BY TYPE,
2023–2030 (USD MILLION) 160
TABLE 118 MIDDLE EAST & AFRICA: BOTULINUM TOXINS MARKET, BY AGE GROUP,
2023–2030 (USD MILLION) 160
TABLE 119 MIDDLE EAST & AFRICA: BOTULINUM TOXINS MARKET, BY APPLICATION,
2023–2030 (USD MILLION) 161
TABLE 120 MIDDLE EAST & AFRICA: BOTULINUM TOXINS MARKET, BY END USER,
2023–2030 (USD MILLION) 161
TABLE 121 GCC COUNTRIES: BOTULINUM TOXINS MARKET, BY TYPE,
2023–2030 (USD MILLION) 162
TABLE 122 REST OF MIDDLE EAST & AFRICA: BOTULINUM TOXINS MARKET, BY TYPE,
2023–2030 (USD MILLION) 162
TABLE 123 OVERVIEW OF STRATEGIES DEPLOYED BY KEY PLAYERS IN BOTULINUM TOXINS MARKET, 2022–2025 163
TABLE 124 BOTULINUM TOXINS MARKET: DEGREE OF COMPETITION 166
TABLE 125 BOTULINUM TOXINS MARKET: REGION FOOTPRINT 174
TABLE 126 BOTULINUM TOXINS MARKET: TYPE FOOTPRINT 175
TABLE 127 BOTULINUM TOXINS MARKET: APPLICATION FOOTPRINT 176
TABLE 128 BOTULINUM TOXINS MARKET: END-USER FOOTPRINT 177
TABLE 129 BOTULINUM TOXINS MARKET: DETAILED LIST OF KEY STARTUPS/SME PLAYERS 180
TABLE 130 BOTULINUM TOXINS MARKET: COMPETITIVE BENCHMARKING OF KEY STARTUPS/SME PLAYERS, BY TYPE AND REGION 181
TABLE 131 BOTULINUM TOXINS MARKET: PRODUCT LAUNCHES & APPROVALS,
JANUARY 2022–JUNE 2025 182
TABLE 132 BOTULINUM TOXINS MARKET: DEALS, JANUARY 2022–JUNE 2025 183
TABLE 133 BOTULINUM TOXINS MARKET: EXPANSIONS, JANUARY 2021–JUNE 2025 184
TABLE 134 ABBVIE INC.: COMPANY OVERVIEW 185
TABLE 135 ABBVIE INC.: PRODUCTS OFFERED 186
TABLE 136 ABBVIE INC.: DEALS, JANUARY 2022–JUNE 2025 187
TABLE 137 ABBVIE INC.: EXPANSIONS, JANUARY 2022–JUNE 2025 188
TABLE 138 ABBVIE INC.: OTHER DEVELOPMENTS, JANUARY 2022–JUNE 2025 188
TABLE 139 IPSEN BIOPHARMACEUTICALS, INC.: COMPANY OVERVIEW 190
TABLE 140 IPSEN BIOPHARMACEUTICALS, INC.: PRODUCTS OFFERED 191
TABLE 141 IPSEN BIOPHARMACEUTICALS, INC.: PRODUCT APPROVALS,
JANUARY 2022–JUNE 2025 192
TABLE 142 IPSEN BIOPHARMACEUTICALS, INC.: EXPANSIONS, JANUARY 2022–JUNE 2025 192
TABLE 143 IPSEN BIOPHARMACEUTICALS, INC.: OTHER DEVELOPMENTS,
JANUARY 2022–JUNE 2025 192
TABLE 144 GALDERMA: COMPANY OVERVIEW 194
TABLE 145 GALDERMA: PRODUCTS OFFERED 195
TABLE 146 GALDERMA: PRODUCT LAUNCHES, JANUARY 2022–JUNE 2025 196
TABLE 147 GALDERMA: DEALS, JANUARY 2022–JUNE 2025 196
TABLE 148 GALDERMA: EXPANSIONS, JANUARY 2022–JUNE 2025 196
TABLE 149 HUGEL, INC.: COMPANY OVERVIEW 198
TABLE 150 HUGEL, INC.: PRODUCTS OFFERED 199
TABLE 151 HUGEL, INC.: PRODUCT APPROVALS, JANUARY 2022–JUNE 2025 200
TABLE 152 HUGEL, INC.: DEALS, JANUARY 2022–JUNE 2025 200
TABLE 153 HUGEL, INC.: EXPANSIONS, JANUARY 2022–JUNE 2025 201
TABLE 154 REVANCE: COMPANY OVERVIEW 202
TABLE 155 REVANCE: PRODUCTS OFFERED 202
TABLE 156 REVANCE: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–JUNE 2025 203
TABLE 157 REVANCE: DEALS, JANUARY 2022–JUNE 2025 203
TABLE 158 EVOLUS, INC.: COMPANY OVERVIEW 205
TABLE 159 EVOLUS, INC.: PRODUCTS OFFERED 206
TABLE 160 EVOLUS, INC.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–JUNE 2025 207
TABLE 161 EVOLUS, INC.: DEALS, JANUARY 2022–JUNE 2025 207
TABLE 162 MEDYTOX: COMPANY OVERVIEW 208
TABLE 163 MEDYTOX: PRODUCTS OFFERED 209
TABLE 164 MEDYTOX: PRODUCT APPROVALS, JANUARY 2022–JUNE 2025 210
TABLE 165 MEDYTOX: DEALS, JANUARY 2022–JUNE 2025 210
TABLE 166 MERZ PHARMA: COMPANY OVERVIEW 211
TABLE 167 MERZ PHARMA: PRODUCTS OFFERED 211
TABLE 168 MERZ PHARMA: PRODUCT APPROVALS, JANUARY 2022–JUNE 2025 212
TABLE 169 SUPERNUS PHARMACEUTICALS, INC.: COMPANY OVERVIEW 213
TABLE 170 SUPERNUS PHARMACEUTICALS, INC.: PRODUCTS OFFERED 214
TABLE 171 DAEWOONG PHARMACEUTICAL CO., LTD.: COMPANY OVERVIEW 215
TABLE 172 DAEWOONG PHARMACEUTICAL CO., LTD.: PRODUCTS OFFERED 215
TABLE 173 DAEWOONG PHARMACEUTICAL CO., LTD.: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–JUNE 2025 216
TABLE 174 HUONS: COMPANY OVERVIEW 217
TABLE 175 HUONS: PRODUCTS OFFERED 218
TABLE 176 HUONS: PRODUCT LAUNCHES & APPROVALS, JANUARY 2022–JUNE 2025 218
TABLE 177 EISAI CO., LTD.: COMPANY OVERVIEW 219
TABLE 178 EISAI CO., LTD.: PRODUCTS OFFERED 220
TABLE 179 HUGH SOURCE (INTERNATIONAL) LTD.: COMPANY OVERVIEW 221
TABLE 180 HUGH SOURCE (INTERNATIONAL) LTD.: PRODUCTS OFFERED 221
TABLE 181 DERMAX CO., LTD.: COMPANY OVERVIEW 222
TABLE 182 GUFIC BIOSCIENCES: COMPANY OVERVIEW 222
TABLE 183 OCEAN PHARMACEUTICAL: COMPANY OVERVIEW 223
TABLE 184 CROMA-PHARMA GMBH: COMPANY OVERVIEW 223
TABLE 185 MICROGEN: COMPANY OVERVIEW 224
TABLE 186 JDBIO CO., LTD.: COMPANY OVERVIEW 224
TABLE 187 CKD BIO: COMPANY OVERVIEW 225
TABLE 188 ATRAZIST ARAY CO.: COMPANY OVERVIEW 225
TABLE 189 GUANGZHOU AOMA BUSINESS CO., LTD.: COMPANY OVERVIEW 226
TABLE 190 JETEMA CO., LTD.: COMPANY OVERVIEW 226
TABLE 191 SINOPHARM GROUP CO., LTD.: COMPANY OVERVIEW 227
TABLE 192 QUFU HANTANG BIOTECHNOLOGY CO., LTD.: COMPANY OVERVIEW 227
FIGURE 1 BOTULINUM TOXINS MARKET SEGMENTATION & REGIONAL SCOPE 25
FIGURE 2 BOTULINUM TOXINS MARKET: YEARS CONSIDERED 27
FIGURE 3 BOTULINUM TOXINS MARKET: RESEARCH DATA 28
FIGURE 4 BOTULINUM TOXINS MARKET: RESEARCH DESIGN 29
FIGURE 5 BOTULINUM TOXINS MARKET: KEY SECONDARY SOURCES 30
FIGURE 6 BOTULINUM TOXINS MARKET: KEY DATA FROM SECONDARY SOURCES 31
FIGURE 7 BOTULINUM TOXINS MARKET: KEY PRIMARY SOURCES
(DEMAND AND SUPPLY SIDES) 32
FIGURE 8 BOTULINUM TOXINS MARKET: KEY SUPPLY- AND DEMAND-SIDE PARTICIPANTS 33
FIGURE 9 BOTULINUM TOXINS MARKET: BREAKDOWN OF PRIMARY INTERVIEWS
(BY COMPANY TYPE, DESIGNATION, AND REGION) 33
FIGURE 10 BOTULINUM TOXINS MARKET: KEY INSIGHTS FROM PRIMARY EXPERTS 34
FIGURE 11 RESEARCH METHODOLOGY: HYPOTHESIS BUILDING 35
FIGURE 12 BOTULINUM TOXINS MARKET: COMPANY REVENUE ESTIMATION 36
FIGURE 13 BOTULINUM TOXINS MARKET: END USER- AND REVENUE-MAPPING-BASED MARKET SIZE ESTIMATION METHODOLOGY 37
FIGURE 14 BOTULINUM TOXINS MARKET: TOP-DOWN APPROACH 38
FIGURE 15 GROWTH PROJECTIONS ON REVENUE IMPACT OF KEY MACROINDICATORS 40
FIGURE 16 BOTULINUM TOXINS MARKET: DATA TRIANGULATION METHODOLOGY 41
FIGURE 17 BOTULINUM TOXINS MARKET, BY PRODUCT, 2025 VS. 2030 (USD MILLION) 44
FIGURE 18 BOTUINUM TOXINS MARKET, BY AGE GROUP, 2025 VS. 2030 (USD MILLION) 45
FIGURE 19 BOTULINUM TOXINS MARKET, BY END USER, 2025 VS. 2030 (USD MILLION) 45
FIGURE 20 BOTULINUM TOXINS MARKET: REGIONAL SNAPSHOT 46
FIGURE 21 INCREASED AESTHETIC CONSCIOUSNESS AND HIGH DISPOSABLE
INCOME TO DRIVE MARKET 47
FIGURE 22 JAPAN AND THERAPEUTIC APPLICATIONS COMMANDED LARGEST
MARKET SHARE IN 2024 48
FIGURE 23 EMERGING MARKETS TO REGISTER HIGHER GROWTH
RATES DURING STUDY PERIOD 49
FIGURE 24 CHINA TO REGISTER HIGHEST CAGR FROM 2025 TO 2030 50
FIGURE 25 BOTULINUM TOXINS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES 51
FIGURE 26 BOTULINUM TOXINS MARKET: TRENDS/DISRUPTIONS IMPACTING CUSTOMER’S BUSINESS 56
FIGURE 27 AVERAGE SELLING PRICE TREND OF BOTULINUM TOXINS, BY KEY PLAYER,
2022–2024 (USD) 57
FIGURE 28 AVERAGE SELLING PRICE TREND OF BOTULINUM TOXINS, BY REGION,
2022–2024 (USD) 58
FIGURE 29 BOTULINUM TOXINS MARKET: VALUE CHAIN ANALYSIS 60
FIGURE 30 BOTULINUM TOXINS MARKET: SUPPLY CHAIN ANALYSIS 62
FIGURE 31 BOTULINUM TOXINS MARKET: ECOSYSTEM ANALYSIS 63
FIGURE 32 BOTULINUM TOXINS MARKET: FUNDING AND NUMBER OF DEALS,
2019–2023 (USD MILLION) 64
FIGURE 33 NUMBER OF DEALS IN BOTULINUM TOXINS MARKET, BY KEY PLAYER,
2019–2023 64
FIGURE 34 VALUE OF DEALS IN BOTULINUM TOXINS MARKET, BY KEY PLAYER,
2019–2023 (USD) 65
FIGURE 35 BOTULINUM TOXINS MARKET: TOP COMPANIES/APPLICANTS FOR BOTULINUM TOXIN PATENTS AND NUMBER OF PATENTS GRANTED, 2015–2025 67
FIGURE 36 BOTULINUM TOXINS MARKET: IMPORT SCENARIO FOR
HS CODE 300290, 2020–2024 (USD) 69
FIGURE 37 BOTULINUM TOXINS MARKET: EXPORT SCENARIO FOR
HS CODE 300290, 2020–2024 (USD) 70
FIGURE 38 BOTULINUM TOXINS MARKET: PORTER’S FIVE FORCES ANALYSIS 85
FIGURE 39 INFLUENCE OF KEY STAKEHOLDERS ON BUYING PROCESS OF BOTULINUM TOXINS, BY TYPE 87
FIGURE 40 KEY BUYING CRITERIA OF BOTULINUM TOXINS, BY END USER 87
FIGURE 41 KEY AI USE CASES IN BOTULINUM TOXINS MARKET 91
FIGURE 42 NORTH AMERICA: BOTULINUM TOXINS MARKET SNAPSHOT 130
FIGURE 43 ASIA PACIFIC: BOTULINUM TOXINS MARKET SNAPSHOT 145
FIGURE 44 REVENUE ANALYSIS OF KEY PLAYERS IN BOTULINUM TOXINS MARKET,
2020–2024 (USD MILLION) 165
FIGURE 45 MARKET SHARE ANALYSIS OF KEY PLAYERS IN BOTULINUM TOXINS MARKET (2024) 166
FIGURE 46 MARKET RANKING OF KEY PLAYERS IN BOTULINUM TOXINS MARKET (2024) 168
FIGURE 47 EV/EBITDA OF TOP THREE PLAYERS (2025) 168
FIGURE 48 YEAR-TO-DATE (YTD) PRICE TOTAL RETURN AND 5-YEAR STOCK BETA OF TOP THREE PLAYERS (2025) 169
FIGURE 49 BOTUNILUM TOXINS MARKET: BRAND/PRODUCT COMPARATIVE ANALYSIS 170
FIGURE 50 BOTULINUM TOXINS MARKET: COMPANY EVALUATION MATRIX
(KEY PLAYERS), 2024 172
FIGURE 51 BOTULINUM TOXINS MARKET: COMPANY FOOTPRINT 173
FIGURE 52 BOULINUM TOXIN MARKET: COMPANY EVALUATION MATRIX
(STARTUPS/SMES), 2024 179
FIGURE 53 ABBVIE INC.: COMPANY SNAPSHOT 186
FIGURE 54 IPSEN BIOPHARMACEUTICALS, INC.: COMPANY SNAPSHOT 191
FIGURE 55 GALDERMA: COMPANY SNAPSHOT 195
FIGURE 56 HUGEL, INC.: COMPANY SNAPSHOT 199
FIGURE 57 EVOLUS, INC.: COMPANY SNAPSHOT 206
FIGURE 58 MEDYTOX: COMPANY SNAPSHOT 208
FIGURE 59 SUPERNUS PHARMACEUTICALS, INC.: COMPANY SNAPSHOT 213
FIGURE 60 HUONS: COMPANY SNAPSHOT 217
FIGURE 61 EISAI CO., LTD.: COMPANY SNAPSHOT 220
同分類最新報告（醫療與生命科學）
查看醫療與生命科學全部報告 →
量子訊息有限公司為 MarketsandMarkets 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們